MedTrace Logo

PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

NCT05310305 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2022-04-11

No results posted yet for this study

Summary

This study is to investigate retrospectively the effects of combination of immune checkpoint inhibitors anti-programmed death-1 antibody (PD-1 antibody) and radiotherapy for recurrent, metastatic and persistent advanced cervical carcinomas. Patients may or may not accept PD-1 antibody as maintenance therapy. Patients are followed up and the survival outcomes are evaluated. The primary endpoint are objective remission rate. The secondary endpoints are progression-free survival, overall survival and severe adverse events.

Conditions

  • Immune Checkpoint Inhibitors
  • Anti-programmed Death-1 Antibody
  • Radiotherapy
  • Recurrent Cervical Carcinoma
  • Metastatic Cervical Carcinoma
  • Persistent Advanced Cervical Carcinoma
  • Objective Remission Rate
  • Progression-free Survival
  • Overall Survival
  • Severe Adverse Events

Interventions

COMBINATION_PRODUCT

Radiotherapy for targeted lesions and PD-1 antibody

Radiotherapy for targeted lesions in all enrolled participants, with concurrent PD-1 antibody. Patients may or may not accept subsequent PD-1 as maintenance therapy.

Sponsors & Collaborators

  • Lei Li

    lead OTHER

Principal Investigators

  • Lei Li, M.D. · Peking Union Medical College Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-26
Primary Completion
2022-09-26
Completion
2023-03-26

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05310305 on ClinicalTrials.gov